TABLE 2.
Overall and size‐specific 10‐year case fatality rates, using different surveillance strategies
| Size of main HCC nodule | No surveillance | US | MRI | |||
|---|---|---|---|---|---|---|
| 12 M | 6 M | 3 M | 12 M | 6 M | ||
| Overall | 77% | 56% | 46% | 39% | 43% | 38% |
| 1–3 cm | 44% | 38% | 37% | 37% | 37% | 37% |
| 3–5 cm | 68% | 62% | 61% | 61% | 61% | 61% |
| >5 cm | 83% | 83% | 83% | 82% | 83% | NA a |
Note: Baseline case scenario relies on a tumor doubling time of 90 days.
Abbreviations: M, month; MRI, magnetic resonance imaging; NA, not adequate; US, ultrasound.
a
NA due to zero hepatocellular carcinoma diagnoses in this subcategory.